The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "
16 December 2024
Eden Research
("Eden" or "the Company")
Appointment of distributor in
Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol products, is pleased to announce it has signed an agreement with Sumi Agro Europe for the distribution of its flagship fungicide, Mevalone®, in
Sumi Agro Europe's appointment as Eden's exclusive distributor expands the companies' partnership across the Central European region, with Sumi Agro Europe already acting as the exclusive distributor for Mevalone in a number of countries, including
Renowned for its dry and delicate Grüner Veltliner grape variety,
As the third largest producer of apples across
Sean Smith, Chief Executive Officer of Eden Research plc, commented:
"As we prepare for a full launch of our product across
Nicola De Tomasso, Business Development Manager in Sumi Agro Europe, commented:
"Eden's mission to bring sustainable agriculture to the industry through plant-derived chemistry has resonated incredibly well with our customers across
- ENDS -
For further information contact:
Eden Research plc |
|
Sean Smith
|
01285 359 555 |
|
|
Cavendish Capital Markets Limited (Nominated advisor and broker) |
|
Giles Balleny / George Lawson (Corporate Finance) Charlie Combe (Broking)
|
020 7397 8900 |
|
|
Hawthorn Advisors (Financial PR) |
|
Victoria Ainsworth
|
|
Notes to Editors:
Eden Research is the only
Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:
Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.
Cedroz™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.
Eden's seed treatment product, EcovelexÔ was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU,
Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises
For more information about Eden, please visit: www.edenresearch.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.